[go: up one dir, main page]

PE65198A1 - Virosomas cationicos como sistema de transferencia para material genetico - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico

Info

Publication number
PE65198A1
PE65198A1 PE1997000354A PE00035497A PE65198A1 PE 65198 A1 PE65198 A1 PE 65198A1 PE 1997000354 A PE1997000354 A PE 1997000354A PE 00035497 A PE00035497 A PE 00035497A PE 65198 A1 PE65198 A1 PE 65198A1
Authority
PE
Peru
Prior art keywords
genetic material
vesicles
cationic
solution
fragment
Prior art date
Application number
PE1997000354A
Other languages
English (en)
Inventor
Peter Klein
Reinhard Gluck
Ernst Rudolf Walti
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of PE65198A1 publication Critical patent/PE65198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIEREN A VESICULAS PROVISTAS DE UNA MEMBRANA DE BICAPA LIPIDICA CATIONICA CAPAZ DE UNIRSE CON UN MATERIAL GENETICO DE CARGA NEGATIVA, EN DONDE DICHAS MEMBRANAS COMPRENDEN: (a) LIPIDOS CATIONICOS Y/O POLICATIONICOS Y/O FOSFATIDILETANOLAMINA Y/O FOSFATIDILCOLINA; (b) AL MENOS UN PEPTIDO DE FUSION VIRAL, TAL COMO LA HEMAGLUTININA (HA) DEL VIRUS DE LA INFLUENZA A; (c) AL MENOS UN MARCADOR CELULAR ESPECIFICO, TAL COMO UN ANTICUERPO MONOCLONAL, UN FRAGMENTO F(ab`)2, UN FRAGMENTO Fab' O UNA CITOQUINA, ENTRE OTROS; (c) AL MENOS UN AGENTE RETICULAR BIFUNCIONAL, TAL COMO UN DERIVADO DE SUCCINIMIDILO HETEROBIFUNCIONAL. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LAS VESICULAS, QUE COMPRENDE: (1) DISOLVER EL PEPTIDO DE FUSION VIRAL EN UN TAMPON HERPES QUE CONTIENE UN DETERGENTE NO IONICO TAL COMO OCTAETILENGLICOL MONODODECILETER Y N-OCTIL-OLIGO-OXIETILENO; (2) ANADIR LIPIDOS CATIONICOS Y/O POLICATIONICOS Y/O UN MARCADOR CELULAR Y/O UN AGENTE RETICULANTE A LA SOLUCION; (3) RETIRAR EL DETERGENTE LAVANDO HASTA 4 VECES LA SOLUCION CON PERLAS MICROPORTADORAS DE POLIESTIRENO; LA SOLUCION RESULTANTE SE SOMETE A ULTRASONIFICACION PARA INCORPORAR EL MATERIAL GENETICO EN LA VESICULAS. ESTE SISTEMA MEJORA LA LIBERACION DEL MATERIAL GENETICO EN LA CELULA DIANA, SIENDO UTIL COMO EQUIPO DE DIAGNOSTICO O EN TERAPIA CONTRA EL CANCER
PE1997000354A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico PE65198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
PE65198A1 true PE65198A1 (es) 1998-10-16

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000354A PE65198A1 (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico

Country Status (28)

Country Link
US (1) US6210708B1 (es)
EP (1) EP0902682A2 (es)
JP (1) JP2000509404A (es)
KR (1) KR100536983B1 (es)
CN (1) CN1271992C (es)
AR (1) AR007054A1 (es)
AU (1) AU710170B2 (es)
BG (1) BG102880A (es)
BR (1) BR9709224A (es)
CA (1) CA2253561A1 (es)
CO (1) CO4600638A1 (es)
CZ (1) CZ299809B6 (es)
EA (1) EA003130B1 (es)
GT (1) GT199700058A (es)
HR (1) HRP970234B1 (es)
HU (1) HUP9901790A3 (es)
ID (1) ID17934A (es)
NO (1) NO327726B1 (es)
NZ (1) NZ332666A (es)
OA (1) OA10916A (es)
PA (1) PA8429201A1 (es)
PE (1) PE65198A1 (es)
PL (1) PL199201B1 (es)
SK (1) SK152698A3 (es)
SV (1) SV1997000032A (es)
TN (1) TNSN97080A1 (es)
WO (1) WO1997041834A1 (es)
ZA (1) ZA973885B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
JP2003512306A (ja) * 1999-10-08 2003-04-02 ニカ ヘルス プロダクツ リミテッド カチオン性ｄｏｓｐｅｒビロソーム
US6722282B2 (en) * 1999-12-17 2004-04-20 Schott Glas Ignition capsule, which can be inductively activated, for occupant restraint systems, and a test circuit for said ignition capsule
EP1252897A4 (en) * 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140335117A1 (en) * 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
WO2018060212A1 (en) 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ATE182791T1 (de) * 1991-05-08 1999-08-15 Schweiz Serum & Impfinst Wiederhergestellte influenza-virosomen mit immunostimulierenden und immunoverstärkenden eigenschaften und diese enthaltende impfstoffe
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
AU2520595A (en) * 1994-05-31 1995-12-21 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
CO4600638A1 (es) 1998-05-08
EA199800992A1 (ru) 1999-06-24
CZ299809B6 (cs) 2008-12-03
AU710170B2 (en) 1999-09-16
WO1997041834A1 (en) 1997-11-13
EP0902682A2 (en) 1999-03-24
US6210708B1 (en) 2001-04-03
CA2253561A1 (en) 1997-11-13
NO327726B1 (no) 2009-09-14
NZ332666A (en) 2000-05-26
KR100536983B1 (ko) 2006-06-29
BG102880A (en) 1999-05-31
KR20000010780A (ko) 2000-02-25
TNSN97080A1 (fr) 2005-03-15
NO985137L (no) 1999-01-04
EA003130B1 (ru) 2003-02-27
HUP9901790A2 (hu) 1999-08-30
CN1271992C (zh) 2006-08-30
JP2000509404A (ja) 2000-07-25
PL329853A1 (en) 1999-04-12
CN1225007A (zh) 1999-08-04
SK152698A3 (en) 1999-05-07
NO985137D0 (no) 1998-11-04
AU2776697A (en) 1997-11-26
BR9709224A (pt) 1999-08-10
SV1997000032A (es) 1998-03-27
ZA973885B (en) 1998-11-06
AR007054A1 (es) 1999-10-13
HRP970234B1 (en) 2002-04-30
PA8429201A1 (es) 2000-05-24
ID17934A (id) 1998-02-12
OA10916A (en) 2003-02-21
PL199201B1 (pl) 2008-08-29
HRP970234A2 (en) 1998-06-30
HUP9901790A3 (en) 2010-11-29
GT199700058A (es) 1998-10-29
CZ361498A3 (cs) 1999-03-17

Similar Documents

Publication Publication Date Title
PE65198A1 (es) Virosomas cationicos como sistema de transferencia para material genetico
ES2118084T3 (es) Anticuerpos anti-icam-1 quimericos humanizados, metodos de preparacion y su uso.
US20170246261A1 (en) Antiviral treatment with low immunogenicity
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
ES2129386T1 (es) Vacuna contra influenza.
ES2153034T3 (es) Sistema de suministro en microparticulas.
SE8205892D0 (sv) Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE335810T1 (de) Verfahren zur inaktivierung von lipidumhüllten viren
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
TR200001842T2 (tr) Papilloma virüs kapsomer aşı formülasyonları- kullanım metotları.
ES2032802T3 (es) Sucedaneo de la sangre, semisintetico, extrapuro.
ES2159564T3 (es) Preparados farmaceuticos para principios activos dificilmente solubles.
CO5690564A2 (es) Medicamento para tratar tejido de miocardio infartado que comprende mioblastos oseos de mamiferos geneticamente modoficados para expresar la proteina sdf-1 de mamifero
MX173942B (es) Dispositivo para la liberacion controlada de po r lo menos una sustancia activa a un ambiente de uso y proceso para preparar el mismo
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
CO4480039A1 (es) Vacunas recombinantes de inmunodeficiencia felina producidas en baculovirus y su uso contra la infeccion de virus de inmunodeficiencia felina
ES2052368T3 (es) Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
AR001399A1 (es) Una composición acondicionadora del cabello.
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ATE244762T1 (de) Säugetier - expressionssysteme für hüllenprotingene des hepatitit - c - virus
BR0110193A (pt) Preparação contendo vwf hemostaticamente ativa e processo para preparação da mesma

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed